2001 Biosimilars Doctors Licensing 
Drug Discovery World
NOVEMBER 9, 2023
Peter O’Callaghan, PhD, Head of Expression System Sciences, Biologics and Licensing, Lonza, on: ‘Solve bispecific heavy-light chain mispairing with bYlok technology’. Alessa Schaffrath, Doctoral Student, UKE Hamburg, on: ‘Transgenic llama mice – a fast and flexible single domain discovery tool’.
FDA Law Blog: Biosimilars
FEBRUARY 11, 2024
Not surprisingly, then-presidential candidate Asa Hutchinson, DEA Administrator from 2001 to 2003, did not sign the letter. Rescheduling would eliminate a tax burden on cannabis companies, allowing licensed companies to expand investments into state programs and focus on public health in collaboration with law enforcement efforts.
Expert insights. Personalized for you.
130 
Let's personalize your content